Spdr S&p Biotech Etf ETF News

Sector ETF report for PBE

The macroeconomic backdrop of Fed interest rate hikes is rapidly deflating overvalued technology companies and "crypto-collectibles." We expect the technology sector to underperform value and biotech.

BofA: If Rates Keep Rising, It Will Soon Be Time To Panic About Currency Debasement BofA''s bearish Chief Investment Strategist, Michael Hartnett, who has been dead on with his fire and brimstone forecasts for the past 6 months, must be getting tired taking victory laps (unlike his Goldman and JPM colleagues who like broken records only know how to repeat BTFD over and over at least until this week when their tune is set to change ). But one thing he may have whiffed on was his tongue-in-cheek suggestion that this weekend we could see an emergency rate hike by the Fed. In his latest Flow Show note titled "Saturday Hike Fever" Hartnett writes that on Saturday Oct 6th 1979 the Fed hiked 100bps (11% to 12%) in response to disorderly 12% inflation. Of course, now inflation is "only" 7.5%, and while there was rampant speculation that we may see an emergency rate hike imminently after the latest CPI print came in red hot - with Hartnett citing Thursday''s probability of Fed hikes intra- meeting in next 3 weeks for 1st time since 1994 just jumped to >25% - this collapsed late on Friday after the Fed unveiled that it would continue its QE tapering until March 9, one week before the next FOMC meeting, taking an early/intermeeting hike off the table.

Opinion Follows Trend. Sentiment is at an extreme low on Biotech and Chinese Tech.

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Our Motley Fool roundtable likes Intercept Pharma, Viking Therapeutics, and Vir Bio.

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Oppenheimer's Jared Holz has four biotech stocks to bet on, after the sector's third worst month ever. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Karen Finerman and Bo

The comments made by a Johnson & Johnson executive earlier this week about biotechnology valuations calls attention to the struggling biotech sector.

They've taken a beating, but the industries they track are still growing.

They've taken a beating, but the industries they track are still growing.

Despite positive material updates, the biotech's shares couldn't escape the market-wide downturn among growth stocks this week.

The XBI Index has had an accumulated collapse in the last year of approximately 50%. It is a historic fall because it had never suffered such a collapse before.

One of the hardest things to do as a day trader is gathering all the necessary information to execute profitable trades. Below are the top 15 charts that can help you stay on top of the markets. Relat

These two clinical-stage biotechs have major upcoming catalysts that could catapult their shares higher.